Quick Answer
Mineralys Therapeutics, Inc. reported Diluted EPS of $2.29 per share (loss) for fiscal year 2025.
Mineralys Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.29 | +37.4% |
| 2024 | -$3.66 | -83.9% |
| 2023 | -$1.99 | +65.5% |
| 2022 | -$5.77 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.52 | +54.0% | +21.2% |
| June 30, 2025 | -$0.66 | +20.5% | +16.5% |
| March 31, 2025 | -$0.79 | -12.9% | +30.1% |
| September 30, 2024 | -$1.13 | -98.2% | -36.1% |
| June 30, 2024 | -$0.83 | -167.7% | -18.6% |
| March 31, 2024 | -$0.70 | -37.3% | -22.8% |
| September 30, 2023 | -$0.57 | +55.8% | -83.9% |
| June 30, 2023 | -$0.31 | +75.4% | +39.2% |
- Mineralys Therapeutics, Inc. showed an increase of +37.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Mineralys Therapeutics, Inc.’s diluted eps has grown by 60.3% (from $5.77 per share (loss) to $2.29 per share (loss)).
- The most recent figure is from Mineralys Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: